HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AWD 12-281

phosphodiesterase 4 inhibitor

Also Known As:

N-(3,5-dichloropyrid-4-yl)-(1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl)glyoxylic acid amide

Networked: 6 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - AWD 12-281: 6
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - AWD 12-281: 6

Experts

1.	Bäumer, Wolfgang: 4 articles (03/2007 - 06/2002)
2.	Hoppmann, Joachim: 4 articles (03/2007 - 06/2002)
3.	Kietzmann, Manfred: 4 articles (03/2007 - 06/2002)
4.	Rundfeldt, Chris: 4 articles (03/2007 - 08/2003)
5.	Ehinger, Andreas M: 2 articles (08/2003 - 06/2002)
6.	Gorr, Gilbert: 2 articles (08/2003 - 06/2002)
7.	Galetzka, Christin: 1 article (12/2005)
8.	Höfgen, Norbert: 1 article (12/2005)
9.	Draheim, Regina: 1 article (02/2004)
10.	Egerland, Ute: 1 article (02/2004)

Related Diseases

1.	Dermatitis 08/01/2003 - "AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis." 08/01/2003 - "AWD 12-281 (N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide), a phosphodiesterase 4 inhibitor, which is optimized for topical administration, was tested in a model of allergic dermatitis in mice. " 06/20/2002 - "Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis." 06/20/2002 - "The inhibitors of the phosphodiesterase 4, SB 207499 (cilomilast, c-4-cyano-4-(3-cyclopentyloxy-4-methoxy-phenyl)-r-L-cyclohexane carboxylic acid) and AWD 12-281 (N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide) were tested in a model of allergic dermatitis in mice. "
2.	Chronic Obstructive Pulmonary Disease (COPD) 10/01/2003 - "These results indicate that AWD 12-281 is a unique potential new drug for the topical treatment of asthma and COPD." 02/01/2004 - "Currently, phase II clinical studies are under way to evaluate the therapeutic potential of AWD 12-281 in asthma, COPD, and allergic rhinitis." 10/01/2003 - "The aim of the current study was to explore the pharmacological profile of intratracheally administered AWD 12-281 in different models of asthma and chronic obstructive pulmonary disease (COPD) in comparison with steroids. "
3.	Asthma (Bronchial Asthma) 10/01/2003 - "These results indicate that AWD 12-281 is a unique potential new drug for the topical treatment of asthma and COPD." 02/01/2004 - "Currently, phase II clinical studies are under way to evaluate the therapeutic potential of AWD 12-281 in asthma, COPD, and allergic rhinitis." 10/01/2003 - "The aim of the current study was to explore the pharmacological profile of intratracheally administered AWD 12-281 in different models of asthma and chronic obstructive pulmonary disease (COPD) in comparison with steroids. "
4.	Allergic Rhinitis 02/01/2004 - "Currently, phase II clinical studies are under way to evaluate the therapeutic potential of AWD 12-281 in asthma, COPD, and allergic rhinitis."
5.	Inflammation (Inflammations) 12/01/2005 - "A further issue was to determine the duration of action and the concentration-response relationship of the topical activity of AWD 12-281 using a model of acute local inflammation--the arachidonic-acid-induced mouse ear oedema. " 12/01/2005 - "The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice." 03/01/2007 - "Consequently, PDE4 inhibitors including cilomilast and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation. "

Related Drugs and Biologics

1.	Phosphodiesterase 4 Inhibitors
2.	Steroids
3.	Cilomilast
4.	Type 4 Cyclic Nucleotide Phosphodiesterases
5.	Arachidonic Acid (Vitamin F)
6.	Cytokines
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
8.	Irritants (Vesicants)
9.	Beclomethasone (Beclometasone)
10.	Amides

Related Therapies and Procedures

1.	Topical Administration